Search Results - Eric Leip

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNE... by Xavier Leleu, Shinsuke Iida, C. Ola Landgren, Alexander Lesokhin, Eric Leip, Arthur Kudla, Gregory Finn, Lugui Qiu

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  2. 2

    P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3 by Xavier Leleu, Noopur Raje, Alexander Lesokhin, Mohamad Mohty, Ajay Nooka, Eric Leip, Sharon T. Sullivan, Andrea Viqueira, Salomon Manier

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  3. 3

    Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study by Jorge E. Cortes, Jeff H. Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H. Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini

    Published in Haematologica (2023-07-01)
    Get full text
    Article


  4. 4

    P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3 by Cyrille Touzeau, Nizar J Bahlis, Christopher Maisel, Lionel Karlin, Asya Nina Varshavsky-Yanovsky, Eric Leip, Umberto Conte, Andrea Viqueira, Sarah M. Larson

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  5. 5

    Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study by Michael H. Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquin Martinez‐Lopez, Guenther Koehne, Paula Rodriguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin

    Published in HemaSphere (2024-07-01)
    Get full text
    Article


  6. 6

    Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study by Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, H. Jean Khoury

    Published in Haematologica (2018-08-01)
    Get full text
    Article


  7. 7

    S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATIO... by Mohamad Mohty, Michael H. Tomasson, Bertrand Arnulf, Nizar J Bahlis, Paula Rodríguez-Otero, Joaquín Martinez-Lopez, Cyrille Touzeau, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Salomon Manier, Noopur Raje, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Akos Czibere, Andrea Viqueira, Alexander Lesokhin

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  8. 8

    P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM... by Salomon Manier, Alexander Lesokhin, Mohamad Mohty, Ruben Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah M. Larson, Asya Nina Varshavsky-Yanovsky, Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J Bahlis, Carlos Fernandez de Larrea, Noopur Raje, Eric Leip, Sharon T. Sullivan, Mohamed Elmeliegy, Andrea Viqueira, Ajay Nooka

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


Search Tools: